BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 18776928)

  • 1. Allo-hematopoietic cell transplantation for Ph chromosome-positive ALL: impact of imatinib on relapse and survival.
    Burke MJ; Trotz B; Luo X; Baker KS; Weisdorf DJ; Wagner JE; Verneris MR
    Bone Marrow Transplant; 2009 Jan; 43(2):107-13. PubMed ID: 18776928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allogeneic hematopoietic cell transplantation (allogeneic HCT) for treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL).
    Burke MJ; Cao Q; Trotz B; Weigel B; Kumar A; Smith A; Verneris MR
    Pediatr Blood Cancer; 2009 Dec; 53(7):1289-94. PubMed ID: 19731318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients.
    Burke MJ; Trotz B; Luo X; Weisdorf DJ; Baker KS; Wagner JE; Verneris MR
    Bone Marrow Transplant; 2009 Aug; 44(3):169-74. PubMed ID: 19204709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of post-transplant imatinib administration on Philadelphia chromosome-positive acute lymphoblastic leukaemia.
    Nishiwaki S; Miyamura K; Kato C; Terakura S; Ohashi K; Sakamaki H; Nakao S; Harigae H; Kodera Y
    Anticancer Res; 2010 Jun; 30(6):2415-8. PubMed ID: 20651401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Administration of imatinib in the first 90 days after allogeneic hematopoietic cell transplantation in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Chen H; Liu KY; Xu LP; Liu DH; Chen YH; Shi HX; Han W; Zhan XH; Wang Y; Zhao T; Huang XJ
    Chin Med J (Engl); 2011 Jan; 124(2):246-52. PubMed ID: 21362375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Imatinib in combination with allogeneic hematopoietic stem cell transplantation improved the outcome of adult Philadelphia chromosome-positive acute lymphoblastic leukemia].
    Cheng Z; Zhao L; Chen G; Wu D; Qiu H; Tang X; Fu C; Jin Z; Chen F; Xue S; Sun A
    Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):114-9. PubMed ID: 24606651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Allogeneic stem cell transplantation for patients with Philadelphia positive leukemia resistant to imatinib].
    Han W; Liu KY; Xu LP; Chen H; Liu DH; Chen YH; Zhang XH; Zhang YC; Chen Y; Wang Y; Wang J; Lu DP; Huang XJ
    Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(28):1974-7. PubMed ID: 19062738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Lee S; Kim YJ; Chung NG; Lim J; Lee DG; Kim HJ; Min CK; Lee JW; Min WS; Kim CC
    Cancer; 2009 Feb; 115(3):561-70. PubMed ID: 19117346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of imatinib therapy on the outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Zhang FH; Ling YW; Zhai X; Zhang Y; Huang F; Fan ZP; Zhou HS; Jiang QL; Sun J; Liu QF
    Hematology; 2013 May; 18(3):151-7. PubMed ID: 23394269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacies of hematopoietic stem cell transplantation plus imatinib in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia: a comparative study].
    Chen J; Wu DP; Chen F; Zhao Y; Sun AN; Qiu HY
    Zhonghua Yi Xue Za Zhi; 2013 Feb; 93(8):583-7. PubMed ID: 23663336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL).
    Ottmann OG; Wassmann B; Pfeifer H; Giagounidis A; Stelljes M; Dührsen U; Schmalzing M; Wunderle L; Binckebanck A; Hoelzer D;
    Cancer; 2007 May; 109(10):2068-76. PubMed ID: 17429836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of minimal residual disease kinetics during imatinib-based treatment on transplantation outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Lee S; Kim DW; Cho BS; Yoon JH; Shin SH; Yahng SA; Lee SE; Eom KS; Kim YJ; Chung NG; Kim HJ; Min CK; Lee JW; Min WS; Park CW
    Leukemia; 2012 Nov; 26(11):2367-74. PubMed ID: 22705993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of prior exposure to imatinib on transplant-related mortality.
    Deininger M; Schleuning M; Greinix H; Sayer HG; Fischer T; Martinez J; Maziarz R; Olavarria E; Verdonck L; Schaefer K; Boqué C; Faber E; Nagler A; Pogliani E; Russell N; Volin L; Schanz U; Doelken G; Kiehl M; Fauser A; Druker B; Sureda A; Iacobelli S; Brand R; Krahl R; Lange T; Hochhaus A; Gratwohl A; Kolb H; Niederwieser D;
    Haematologica; 2006 Apr; 91(4):452-9. PubMed ID: 16585011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical study of Philadelphia chromosome-positive acute lymphoblastic leukemia].
    Bao L; Jiang B; Huang XJ; Wang DB; Qiu JY; Lu XJ; Chen H; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):31-4. PubMed ID: 15946506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intermediate dose of imatinib in combination with chemotherapy followed by allogeneic stem cell transplantation improves early outcome in paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (ALL): results of the Spanish Cooperative Group SHOP studies ALL-94, ALL-99 and ALL-2005.
    Rives S; Estella J; Gómez P; López-Duarte M; de Miguel PG; Verdeguer A; Moreno MJ; Vivanco JL; Couselo JM; Fernández-Delgado R; Maldonado M; Tasso M; López-Ibor B; Lendínez F; López-Almaraz R; Uriz J; Melo M; Fernández-Teijeiro A; Rodríguez I; Badell I
    Br J Haematol; 2011 Sep; 154(5):600-11. PubMed ID: 21707583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia.
    Pfeifer H; Wassmann B; Bethge W; Dengler J; Bornhäuser M; Stadler M; Beelen D; Vucinic V; Burmeister T; Stelljes M; Faul C; Dreger P; Kiani A; Schäfer-Eckart K; Schwerdtfeger R; Lange E; Kubuschok B; Horst HA; Gramatzki M; Brück P; Serve H; Hoelzer D; Gökbuget N; Ottmann OG;
    Leukemia; 2013 Jun; 27(6):1254-62. PubMed ID: 23212150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-transplant imatinib-based therapy improves the outcome of allogeneic hematopoietic stem cell transplantation for BCR-ABL-positive acute lymphoblastic leukemia.
    Mizuta S; Matsuo K; Yagasaki F; Yujiri T; Hatta Y; Kimura Y; Ueda Y; Kanamori H; Usui N; Akiyama H; Miyazaki Y; Ohtake S; Atsuta Y; Sakamaki H; Kawa K; Morishima Y; Ohnishi K; Naoe T; Ohno R
    Leukemia; 2011 Jan; 25(1):41-7. PubMed ID: 20944676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prognostic significance of Ph-positive acute lymphoblastic leukemia].
    Zhou L; Hu J; Chen J; Du S; Wang A; You J; Wu W; Shen Z; Li J
    Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):109-13. PubMed ID: 24606650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Imatinib combined with modified hyper-CVAD/MA followed by allogeneic hematopoietic stem cell transplantation in CR1 as the front-line therapy for adult Ph(+) acute lymphoblastic leukemia].
    Huang J; Zou DH; Fu MW; Li ZJ; Xu Y; Zhao YZ; Qi JY; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2011 Oct; 32(10):673-8. PubMed ID: 22339825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical study of Philadelphia chromosome-positive adult acute lymphoblastic leukemia].
    Zhang YF; Chen ZM; Lou JY; Ni WM; Wang YG; Meng HT; Tong HY; Qian WB; Jin J
    Zhonghua Xue Ye Xue Za Zhi; 2011 Dec; 32(12):814-8. PubMed ID: 22339953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.